hotspot -WSS

hotspot

author：fashion 2025-09-30 16:27:46 - browse：8722

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Roche acquires Telavant from Roivant, adding experimental IBD treatment

WSS

Smaller biotechs seek to piggyback on weight loss drug boom

CZI to create biohub to build anti

Cassava Sciences’ Alzheimer’s clinical trials should be halted

STAT Readout: Friday, Oct. 20 biotech updates

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Why a market frenzy over new weight loss drugs defies logic

leisure time

hotspot

explore

Virginia high school admissions case could be legal follow

Readout LOUD podcast: Live from the 2023 STAT Summit

After affirmative action ruling, medical educators look to 'holistic review'

Roivant's CEO is a star, but biotech's black hole persists

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Activists slam private health insurers over coverage restrictions

Roivant's CEO is a star, but biotech's black hole persists

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Summit: Ending the crisis of Black deaths in the U.S.

entertainment

ADCs take center stage as promising cancer treatments

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Summit: The economic case for universal basic health care

STAT Summit: The economic case for universal basic health care

STAT Readout Newsletter: Biotech news today

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

knowledge

focus

hotspot

Wikipedia